| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454024 | Lung Cancer | 2018 | 6 Pages |
Abstract
In previously treated patients with advanced KRAS mutant NSCLC, the combination of the MET inhibitor tivantinib and erlotinib is not superior to conventional single-agent chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
David E. Gerber, Mark A. Socinski, Joel W. Neal, Heather A. Wakelee, Keisuke Shirai, Lecia V. Sequist, Rachel P. Rosovsky, Rogerio C. Lilenbaum, Bruno R. Bastos, Chao Huang, Melissa L. Johnson, Paul J. Hesketh, Deepa S. Subramaniam, Martin F. Dietrich,